{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"International, multicenter, non-interventional PASS study  to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings","eudractNumber":null,"id":11259,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T15:34:09+02:00","shortTitle":"MagnetisMM-16","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","eudractNumber":"2021-002531-27","id":10386,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05243797","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-08-29T12:41:01+02:00","shortTitle":"MajesTEC-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC \nand Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and \nLenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in \nParticipants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended \nfor Autologous Stem Cell Transplant as Initial Therapy ","eudractNumber":"2022-000909-28","id":9487,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05552222","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T12:39:06+02:00","shortTitle":"MajesTEC-7, 64007957MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
MEGA-Studie - Minimal invasive versus offene Gastrektomie. Eine multizentrische randomisierte kontrollierte Studie
DRKS00025765



","eudractNumber":null,"id":9153,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-02-01T13:07:58+01:00","shortTitle":"Mega Trial","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Genetische Veränderungen, Therapieansprechen und Resistenzentwicklung beim Melanom","eudractNumber":null,"id":2136,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-11-20T09:42:29+01:00","shortTitle":"Melanom Sequenzierungsprojekt (Melaseq)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focos on digital side effect management","eudractNumber":"2021-000287-30","id":8045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"}],"nctNumber":"NCT05362760","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-12-01T15:29:48+01:00","shortTitle":"Minerva","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Molecular Mechanisms of Therapy resistant breast cancer,
prospektive, nicht-interventionelle Registerstudie mit integrierter Biomaterialsammlung

DRKS00033761
","eudractNumber":null,"id":11722,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2026-09-29T08:25:31+02:00","shortTitle":"Momentum","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2
Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

","eudractNumber":"2024-517140-65","id":11953,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BCL (B-cell lymphoma)","id":"mt_202"},{"name":"BCL-2","id":"mt_74"},{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT06953960","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2026-04-30T12:43:33+02:00","shortTitle":"Multiple Myeloma: Evaluate the Safety and Efficacy of ABBV-453 in Monotherapy or in Combination with Antimyeloma Regimens","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"MYRIAM: Clinical Research platform for molecular testing, treatment and outcome of patients with Multiple Myeloma (Myeloma Registry Platform: MYRIAM)","eudractNumber":null,"id":4528,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03308474","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-01-18T12:17:40+01:00","shortTitle":"Myeloma Registry Platform (MYRIAM)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

ENCLOSE (Klinische Studiengruppe NAFLD): CK18 M30 als\nnicht-invasiver Marker für subklinische Zellschädigung – prospektive Analyse\ndes Langzeitverlaufes bei NAFLD

","eudractNumber":null,"id":2266,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"Caspase-cleaved fragment of CK18 (M30)","id":"mt_271"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-07-01T09:39:14+02:00","shortTitle":"NAFLD CSG","therapeutical":false,"therapyLines":[]}]}